Navigation Links
DNA-bound p53 Tumor Suppressor Protein Structure Determined

More than half of human cancers involve mutations in the p53 tumor-suppressor gene, suggesting the critical role played by the normal p53 protein in defending// against cancer. Similarly, roughly 95 percent of cancer-causing mutations in the p53 protein occur in its DNA-binding core domain, pointing to this region of the p53 protein as being pivotal to its anti-cancer activity.

Clearly, a detailed view of the p53 protein in direct contact with DNA could provide important insights into preventing and treating an array of human cancers. To date, however, despite having learned a good deal about the protein’s biochemistry over the years, scientists have been unable to "see" the protein – using the tools of structural biology – bound to DNA in its naturally occurring form. This naturally occurring form contains a pairing of two p53 proteins, called a dimer, that then binds to a second p53 dimer in a similar way to create the precisely oriented four-protein complex, called a tetramer, that binds DNA.

Now, in a new study featured as a "paper of the week" and on the cover of the July 21 issue of the Journal of Biological Chemistry, researchers at The Wistar Institute have successfully determined the three-dimensional structure of the p53 protein bound as a dimer to DNA and used the structure to produce an accurate model of the p53 tetramer bound to DNA.

"The bottom line is that we now have a detailed picture of how p53 binds DNA," says Ronen Marmorstein, Ph.D., a professor in the Gene Expression and Regulation Program at Wistar and senior author on the study. "Given the fact that p53 is an important tumor suppressor that is mutated in the majority of human cancers, this will undoubtedly be useful information."

Earlier work had shown how p53 binds to DNA as a stand-alone entity, a form that does not represent the natural state of p53 binding to DNA. The present work captures p53 bound to DNA in its natural dimeric units and th us allows Marmorstein and colleagues to make new and potentially significant insights into p53 function.

One new insight from the current study, for example, is that the point of contact between the two core domains of a pair of p53 proteins forming a dimer tracks to a part of the protein often mutated in cancers. This suggests that the interface between the two proteins of the dimer is likely as important for the proper functioning of the tetramer as its interface with DNA, which also depends on the interface of the core domains of the two p53 proteins that form a dimer.

In seeking to determine the structure of p53 bound to DNA, the challenge for the scientists was that their efforts to crystallize the p53 dimer bound to DNA consistently resulted in structures that could not bind to DNA. (Crystallization is a prerequisite for obtaining the type of three-dimensional image sought in this study.) The researchers found that the dimers formed in solution prior to crystallization attempts took on a form that was incompatible with DNA binding.

"There's an inactive form of the p53 dimer that's unable to bind DNA in the correct fashion," Marmorstein explains. "We knew there had to be a structural rearrangement of the core domains to allow p53 to bind DNA as a dimer. The core domain is what's binding the DNA, but within the dimer, the two cores have to be in the proper orientation to bind DNA.

"So we decided that we needed to somehow lock the protein into a conformation that's compatible with the dimer binding to DNA. We used a chemical trick in which we modified a DNA base to allow it to attach directly to a part of the protein's core domain. That allowed us to trap the form of the p53 dimer that’s compatible with DNA binding. And we solved the structure. We saw what it looked like."

(Source: Newswis)
'"/>




Related medicine news :

1. Use of Cellular Phones associated with Increased risk of Brain Tumors
2. Radiofrequency Energy Cooks Tumors Without Surgery
3. New Liver Tumor Treatment
4. Latest Tumor Classification More Informative
5. New Technique For Benign Breast Tumors
6. Another Treatment Option for Benign Tumors
7. Understanding The Origin Of Tumors
8. Outpatient Treatment Possible For Patients with Uterine Fibroid Tumors
9. Stem Cells, Tumor Cells Share Similar Properties: Scope For Treatment and Prevention?
10. Lipoma Arborescens: A Rare Tumor Of The Knee
11. Researchers Develop Mouse Model Of Brain Tumor
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... ... 06, 2016 , ... U.S. Security Associates (USA) was named ... their industry leading training methods that engage their associates and link their achievements ... elite in employer-sponsored training and development programs. , “The 2017 Training Top 125 ...
(Date:12/5/2016)... ... ... For many years, Andrew G. Zubinas has accumulated over 130 hardcover ... Lithuanian language and its poetry inspired him in writing “ Forest Lungs ... aspects of a living, breathing forest where nothing ever stays the same. His subjects ...
(Date:12/5/2016)... ... 05, 2016 , ... “Epilepsy Awareness,” which can be found ... a conversation about epilepsy, bearing down on the social stigma and lack of ... with epilepsy within their lifetime. With such a large percentage of people affected, ...
(Date:12/5/2016)... , ... December 05, 2016 , ... BSI and Brenntag ... United States and Canada for distribution of their natural fruits and beverage ... is an exciting addition to our Life Sciences product portfolio,” said Steve Brauer, ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... portfolio company, today announced it has acquired the assets of Frankfurt, Germany ... a subsidiary of Chiltern International and focuses on clinical trial drug packaging, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 5, 2016 Special purpose needles are used in ... fluid and cells from organs or lumps and are available ... The global market for special purpose needles is showing a ... of revenue, the global special purpose needles market is projected ... period (2016–2026) and is expected to be valued at US$ ...
(Date:12/5/2016)... Dec. 5, 2016  Pennsylvania Physician General Dr. ... Programs Gary Tennis today filled prescriptions for ... Pharmacy in York to demonstrate ... Dr. Levine as a prescription to acquire naloxone at ... important to remember that any Pennsylvanian can walk up ...
(Date:12/5/2016)... -- Research and Markets has announced the addition ... (Biomedical & Biochemical Research, Disease Diagnostics), End User (Academic & Research ... report to their offering. ... , The western blotting ... USD 574.8 Million in 2016, growing at a CAGR of 4.9%. ...
Breaking Medicine Technology: